Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.69 |
| ▸ | NPC1 | O15118 | 9/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.60 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.57 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29723905 | 0.84 | KDR (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL259238 | 0.84 | KDR (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL30643208 | 0.84 | KDR (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL12010995 | 0.83 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL18027795 | 0.82 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL11078736 | 0.82 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL1452104 | 0.82 | RAB9A (0.71) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3118458 | 0.81 | KMT2A (0.62) | SMN1; SMN2GAAALDH1A1MAPTMEN1 | |
| SCHEMBL2490566 | 0.81 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL12764166 | 0.81 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230191383-A1 | FORMULATIONS FOR METAL CATALYSIS IN WATER COMPRISING A SURFACTANT AND A LIPOPHILIC COMPOUND | UNIVERSITE DE MONTPELLIER (FR) | 2023-06-22 | — | — | US | disclosed |
| WO-2023009475-A1 | ROCK2 INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-112047879-B | Method for selectively synthesizing halogenated arylamine by copper catalysis | 浙江工业大学 | 2022-01-14 | — | — | CN | disclosed |
| CN-112047879-A | Method for selectively synthesizing halogenated arylamine by copper catalysis | 浙江工业大学 | 2020-12-08 | — | — | CN | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-8067586-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | HAYAKAWA MASAHIKO | 2010-06-03 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-20070037805-A1 | Fused heteroaryl derivatives | HAYAKAWA MASAHIKO | 2007-02-15 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
| US-7173029-B2 | Fused heteroaryl derivatives | ASTELLAS PHARMA INC. (JP) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137584-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | RAB9A 613/4885NPC1 1963/4885SMN1; SMN2 4764/4885 |
| US-20070037805-A1 | Fused heteroaryl derivatives | PIK3CD, PIK3R3, PIK3C2A | RAB9A 613/4885NPC1 1963/4885SMN1; SMN2 4764/4885 |
| US-20100137585-A1 | FUSED HETEROARYL DERIVATIVES | PIK3CD, PIK3R3, PIK3C2A | RAB9A 613/4885NPC1 1963/4885SMN1; SMN2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.